E-ISSN: 2147-2688
Cytoreductive Surgery and Hyperthermic İntraperitoneal Chemoterapy for Advance Gastric Cancer Associated Peritoneal Carcinomatosis Single Centre Unit for 10 Consecutive Patients
PDF
Cite
Share
Request
Original Article
VOLUME: 57 ISSUE: 3
P: 267-273
September 2019

Cytoreductive Surgery and Hyperthermic İntraperitoneal Chemoterapy for Advance Gastric Cancer Associated Peritoneal Carcinomatosis Single Centre Unit for 10 Consecutive Patients

Med Bull Haseki 2019;57(3):267-273
DOI: 10.4274/haseki.galenos.2019.4997
Özgül Düzgün 1
Sema Yüksekdağ 1
Murat Kalın 1
Şenol Çomoğlu 2
Semra Yanık 3
Ömer Faruk Özkan 1
Neşet Köksal 4
1. Sağlık Bilimleri Üniversitesi, Ümraniye Eğitim ve Araştırma Hastanesi, Genel Cerrahi Kliniği, İstanbul, Türkiye
2. Sağlık Bilimleri Üniversitesi, Ümraniye Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İstanbul, Türkiye
3. Sağlık Bilimleri Üniversitesi, Ümraniye Eğitim ve Araştırma Hastanesi, Anestezi ve Reanimasyon Kliniği, İstanbul, Türkiye
4. Yeditepe Üniversitesi Tıp Fakültesi Hastanesi, Genel Cerrahi Kliniği, İstanbul, Türkiye
No information available.
No information available
Received Date: 07.02.2019
Accepted Date: 07.03.2019
Publish Date: 20.09.2019
PDF
Cite
Share
Request

ABSTRACT

Aim:

Hyperthermic intraperitoneal chemotherapy with cytoreductive surgery has a positive effect on survival in advanced abdominal cancers. We aimed to present our experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer patients with peritoneal carcinomatosis and a review of the literature.

Methods:

Ten patients (seven male, three female) who were diagnosed with gastric cancer between June 2017 and November 2018 were included in the study. Data on demographic characteristics, short-term follow-up results, surgical findings, peritoneal carcinomatosis index score, completeness of cytoreduction score, and morbidity and mortality rates were retrospectively analyzed.

Results:

The mean age of the patients was 60.3 years. The mean follow-up period was six months (1-15 months). One patient developed an anastomotic leak. In the other nine cases, there was no morbidity leading to mortality.

Conclusion:

While gastric cancer with peritoneal carcinomatos has a poor survival, less than six months with non-operative approach, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy offers better outcomes and overall survival. Our first results in our study with a limited number of patients are satisfactory and multicentric randomized studies are needed on this subject.

References

1Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: e359-86.
2Polom K, Marano L, Roviello G, et al. Evolution and emerging future of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence. Int J Hyperthermia 2016;32:173-9.
3Geng X, Liu H, Lin T, et al. Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensityscore matched analysis. Cancer Med  2016;5:2781-91.
4Kim GH, Liang PS, Bang SJ, et al. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointest Endosc 2016;84:18-28.
5Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol 2015;21:10936-47.
6Ji ZH, Peng KW, Yu Y, et al. Current status and future  prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia 2017;33:562-70.
7Yarema RR, Ohorchak MA, Zubarev GP, et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: results of a single-centre retrospective study. Int J Hyperthermia 2014;30:159-65.
8Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 2016;21:1114-30.
9Boerner T, Graichen A, Jeiter T, et al. CRS-HIPEC Prolongs Survival but is Not Curative for Patients with Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol 2016;23:3972-7.
10Morales-Soriano R, Esteve-Pérez N, Segura-Sampedro JJ, et alCurrent practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanishmulticentric survey. Eur J Surg Oncol 2018;44:228-36.
11Ellison LM, Man Y, Stojadinovic A, Xin H, Avital I. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis. Chin J Cancer Res 2017;29:86-92.
12Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 2012;12:526-9.
13Braam HJ, Schellens JH, Boot H, et al. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit Rev Oncol Hematol 2015;95:282-96.
14Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 2014;40:12-26.
15Tu Y, Tian Y, Fang Z, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study. Int J Hyperthermia 2016;32:587-94.
16Wei J, Wu ND, Liu BR. Regional but fatal: Intraperitoneal metastasis in gastric cancer. World J Gastroenterol 2016;22:7478-85.
17Feingold PL, Kwong ML, Davis JL, et al. Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review. J Surg Oncol 2017;115:192-201.
18Murata S, Yamamoto H, Naitoh H, et al. Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5 fluorouracilcombined with cisplatin and mitomycin C in patients undergoing gastrectomy for advancedgastric cancer. J Surg Oncol 2017;116:1159-65.
19Tentes AA, Pallas N, Karamveri C, et al. Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer. J BUON 2018;23:482-87.
20Sugarbaker PH. Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy. Tech Coloproctol 2005;9:95-103.
21Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol 2015;41:911-9.
22Chia CS, You B, Decullier E, et al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgeryand Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol 2016;23:1971-9.
23Wu HT, Peng KW, Ji ZH, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.Eur J Surg Oncol 2016;42:1024-34.
24Wu Z, Li Z, Ji J. Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced gastric cancer. Transl Gastroenterol Hepatol 2016;1:63.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House